Grammati Sarri

Executive Research Principal, HTA and Health Policy, Market Access

Grammati brings a wealth of experience to her role at Cytel having worked in private consultancies, leading ​​Health Economics and Outcomes Research (HEOR) projects and providing strategic guidance on evidence synthesis and clinical effectiveness analyses for early product value demonstration and ​Health Technology Assessment (HTA) submissions.

She has gained ​​Real-World Evidence (RWE) expertise in leveraging this data for healthcare decision-making through her ISPE leading role in producing guidance documents. This includes developing an RWE framework for combining evidence from different sources (work recognized by NICE, EU HTA project), using electronic health records (for COVID-19), and ongoing collaborations with key stakeholders (Harvard Medical School, Utrecht University, NICE).

Grammati previously worked for Evidera and Visible Analytics. She also had a senior leadership role in the development of NICE Guidelines, working closely with clinicians, patients, and NICE executives. She holds a Masters in Dental Public Health from Queen Mary University London and a PhD in Oral Epidemiology from UCL.